Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026

Same author

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Blood·2026

Same author

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Blood·2025

Same author

The management of myelofibrosis: A British Society for Haematology Guideline.

British journal of haematology·2023

Same author

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

British journal of haematology·2023

Same author

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.

American journal of hematology·2023

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting treatment in AML.

Alan K Burnett¹, Steve Knapper

¹Heath Park, School of Medicine, Cardiff Univ., Cardiff CF4 4XN, United Kingdom. burnettak@cardiff.ac.uk

Hematology. American Society of Hematology. Education Program

|November 21, 2007

Summary

Chemotherapy for acute myeloid leukemia (AML) shows limited progress. New targeted treatments focus on molecular and immunophenotypic characteristics, including CD33 and FLT-3 mutations, for better patient outcomes.

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Current chemotherapy for acute myeloid leukemia (AML) may have reached its therapeutic limit.
Advances in understanding AML's molecular, immunophenotypic, and biological features are crucial for developing next-generation treatments.
Personalized medicine approaches are needed, integrating disease characteristics with patient biology.

Purpose of the Study:

To explore novel therapeutic strategies for acute myeloid leukemia (AML) by leveraging recent scientific discoveries.
To identify and discuss potential molecular and cellular targets for more effective AML treatment.
To evaluate the potential of antibody-directed therapies, immunophenotypic markers, and molecular abnormalities in AML management.

Main Methods:

Related Experiment Videos

Last Updated: Jul 10, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Review of current literature on AML treatment and emerging therapeutic targets.

Analysis of immunophenotypic markers like CD33 for antibody-directed therapy.

Investigation of molecular abnormalities, including FLT-3 mutations, farnesylation, methylation, and histone deacetylation.

Exploration of leukemic stem cell biology for targeted interventions.

Main Results:

Immunophenotyping identified CD33 as a target for antibody-directed therapy, showing response rates in relapsed disease.
Minimal residual disease (MRD) detection and molecular markers (e.g., FLT-3 mutations) can identify high-risk patients, though intervention timing is unclear.
Targeting mechanisms like farnesylation, methylation, and histone deacetylation are under investigation.
Understanding leukemic stem cell characteristics offers new avenues for targeted treatment development.

Conclusions:

Targeted therapies, including antibody-directed treatments and agents against specific molecular abnormalities like FLT-3 mutations, hold promise for AML.
Further research and clinical trials are necessary to establish the efficacy of these novel approaches, particularly in combination with chemotherapy.
Exploiting the unique biological features of leukemic stem cells represents a promising frontier in AML treatment development.